LIGAND PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

LGND$314.15+2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except par value)

	December 31,
	2024	2023
ASSETS
Current assets:
Cash and cash equivalents	$72,307	$22,954
Short-term investments	183,858	147,355
Accounts receivable, net	38,376	32,917
Inventory	14,114	23,969
Income taxes receivable	4,073	6,395
Prepaid expenses	1,934	1,182
Other current assets	16,897	2,657
Total current assets	331,559	237,429
Intangible assets, net	266,648	299,606
Goodwill	105,250	103,370
Long-term portion of financial royalty assets, net	185,024	62,291
Noncurrent derivative assets	10,583	3,531
Property and equipment, net	15,133	15,607
Operating lease right-of-use assets	6,907	6,062
Finance lease right-of-use assets	2,766	3,393
Equity method investment in Primrose Bio	—	12,595
Other investments	10,908	36,726
Deferred income taxes, net	72	214
Other assets	6,924	6,392
Total assets	$941,774	$787,216
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$5,233	$2,427
Accrued liabilities	27,906	12,467
Income tax payable	1,199	—
Deferred revenue	1,278	1,222
Current contingent liabilities	206	256
Current operating lease liabilities	1,266	403
Current finance lease liabilities	24	7
Total current liabilities	37,112	16,782
Long-term deferred revenue	2,246	1,444
Long-term contingent liabilities	3,475	2,942
Long-term operating lease liabilities	5,815	5,755
Deferred income taxes, net	32,524	31,622
Other long-term liabilities	30,163	27,758
Total liabilities	111,335	86,303
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023	—	—
Common stock, $0.001 par value; 60,000 shares authorized; 19,106 and 17,556 shares issued and outstanding at December 31, 2024 and 2023, respectively	20	18
Additional paid-in capital	337,377	198,696
Accumulated other comprehensive loss	(5,942)	(817)
Retained earnings	498,984	503,016
Total stockholders’ equity	830,439	700,913
Total liabilities and stockholders’ equity	$941,774	$787,216

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.